Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Taiji Yoshino is active.

Publication


Featured researches published by Taiji Yoshino.


Journal of Immunology | 2003

A pyrazole derivative, YM-58483, potently inhibits store-operated sustained Ca2+ influx and IL-2 production in T lymphocytes

Jun Ishikawa; Keiko Ohga; Taiji Yoshino; Ryuichi Takezawa; Atsushi Ichikawa; Hirokazu Kubota; Toshimitsu Yamada

In nonexcitable cells, Ca2+ entry is mediated predominantly through the store depletion-dependent Ca2+ channels called store-operated Ca2+ (SOC) or Ca2+ release-activated Ca2+ channels. YM-58483, a pyrazole derivative, inhibited an anti-CD3 mAb-induced sustained Ca2+ influx in acute T cell leukemia, Jurkat cells. But it did not affect an anti-CD3 mAb-induced transient intracellular Ca2+ increase in Ca2+-free medium, nor anti-CD3 mAb-induced phosphorylation of phospholipase Cγ1. It was suggested that YM-58483 inhibited Ca2+ influx through SOC channels without affecting the TCR signal transduction cascade. Furthermore, YM-58483 inhibited thapsigargin-induced sustained Ca2+ influx with an IC50 value of 100 nM without affecting membrane potential. YM-58483 inhibited by 30-fold the Ca2+ influx through SOC channels compared with voltage-operated Ca2+ channels, while econazole inhibited both SOC channels and voltage-operated Ca2+ channels with an equivalent range of IC50 values. YM-58483 potently inhibited IL-2 production and NF-AT-driven promoter activity, but not AP-1-driven promoter activity in Jurkat cells. Moreover, this compound inhibited delayed-type hypersensitivity in mice with an ED50 of 1.1 mg/kg. Therefore, we concluded that YM-58483 was a novel store-operated Ca2+ entry blocker and a potent immunomodulator, and could be useful for the treatment of autoimmune diseases and chronic inflammation. Furthermore, YM-58483 would be a candidate for the study of capacitative Ca2+ entry mechanisms through SOC/CRAC channels and for identification of putative Ca2+ channel genes.


Luts: Lower Urinary Tract Symptoms | 2016

Study on Physiological Roles of Stimulation of Prostaglandin E2 Receptor Subtype EP2 in Urethral Function in Rats.

Ryoko Kurihara; Kenichiro Ishizu; Hajime Takamatsu; Taiji Yoshino; Noriyuki Masuda

We investigated the relaxant effect of stimulation of prostaglandin E2 (PGE2) receptor subtype EP2 as well as the involvement of a cyclic AMP (cAMP)‐dependent pathway related to stimulation of EP2 receptors in urethral function in rats by evaluating effects of PGE2 and selective EP2 receptor agonist CP‐533,536.


Luts: Lower Urinary Tract Symptoms | 2016

Effect of Selective Prostaglandin E2 EP2 Receptor Agonist CP-533,536 on Voiding Efficiency in Rats with Midodrine-Induced Functional Urethral Obstruction.

Ryoko Kurihara; Katsunori Imazumi; Hajime Takamatsu; Kenichiro Ishizu; Taiji Yoshino; Noriyuki Masuda

We investigated the effect of the selective prostaglandin E2 EP2 receptor agonist CP‐533,536 on voiding efficiency in rats with midodrine‐induced functional urethral obstruction.


Luts: Lower Urinary Tract Symptoms | 2018

Intratesticular Bradykinin Involvement in Rat Testicular Pain Models

Kenichiro Fujimoto; Taiji Yoshino; Katsuro Yoshioka; Hironori Yuyama; Noriyuki Masuda; Masahiro Takeda

To clarify the role of bradykinin in urogenital pain, we investigated bradykinin involvement in rat models of testicular pain.


Luts: Lower Urinary Tract Symptoms | 2017

Physiological Roles of Bradykinin and Involvement of Bradykinin B2 Receptor in Urethral Function in Humans and Animals.

Kenichiro Fujimoto; Taiji Yoshino; Satoko Nakajima; Hironori Yuyama; Noriyuki Masuda; Masahiro Takeda

We investigated the role of bradykinin in urethral function by examining contractile responses in urethral smooth muscle strips isolated from humans and the intraurethral pressure in rats and dogs.


European Journal of Pharmacology | 2007

YM-58483, a selective CRAC channel inhibitor, prevents antigen-induced airway eosinophilia and late phase asthmatic responses via Th2 cytokine inhibition in animal models

Taiji Yoshino; Jun Ishikawa; Keiko Ohga; Tatsuaki Morokata; Ryuichi Takezawa; Hiroki Morio; Youhei Okada; Kazuo Honda; Toshimitsu Yamada


Bioorganic & Medicinal Chemistry | 2008

Novel potent and selective Ca2+ release-activated Ca2+ (CRAC) channel inhibitors. Part 3: Synthesis and CRAC channel inhibitory activity of 4'-[(trifluoromethyl)pyrazol-1-yl]carboxanilides

Yasuhiro Yonetoku; Hirokazu Kubota; Yoji Miyazaki; Yoshinori Okamoto; Masashi Funatsu; Noriko Yoshimura-Ishikawa; Jun Ishikawa; Taiji Yoshino; Makoto Takeuchi; Mitsuaki Ohta


Pulmonary Pharmacology & Therapeutics | 2008

The suppressive effects of YM-58483/BTP-2, a store-operated Ca2+ entry blocker, on inflammatory mediator release in vitro and airway responses in vivo

Keiko Ohga; Ryuichi Takezawa; Taiji Yoshino; Toshimitsu Yamada; Yasuaki Shimizu; Jun Ishikawa


European Journal of Pharmacology | 2005

Effect of celecoxib, a cyclooxygenase-2 inhibitor, on the pathophysiology of adjuvant arthritis in rat.

Masahiro Noguchi; Aishi Kimoto; Seiji Kobayashi; Taiji Yoshino; Keiji Miyata; Masao Sasamata


European Journal of Pharmacology | 2005

Effects of solifenacin succinate (YM905) on detrusor overactivity in conscious cerebral infarcted rats.

Masanori Suzuki; Akiyoshi Ohtake; Taiji Yoshino; Hironori Yuyama; Aska Hayashi; Masashi Ukai; Hiroko Okutsu; Yukiko Noguchi; Shuichi Sato; Masao Sasamata

Collaboration


Dive into the Taiji Yoshino's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge